NasdaqGS - Delayed Quote USD

Krystal Biotech, Inc. (KRYS)

158.53 -5.44 (-3.32%)
At close: April 19 at 4:00 PM EDT
159.17 +0.64 (+0.40%)
After hours: April 19 at 4:19 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Krish S. Krishnan M.B.A., M.S. Founder, Chairman, President & CEO 1.32M -- 1965
Ms. Suma M. Krishnan Founder, President of R&D and Director 895.33k -- 1965
Ms. Kathryn A. Romano Executive VP & Chief Accounting Officer 614.87k 2.35M 1982
Mr. John Thomas General Counsel & Corporate Secretary -- -- --
Mr. John Karakkal Vice President of North American Sales & Marketing -- -- --
Ms. Christine Wilson Head of U.S. Sales and Marketing -- -- --
Mr. Josh Suskin Director of Human Resources & Operations -- -- --
Mr. Laurent Goux Senior VP & GM of Europe -- -- --

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830 https://www.krystalbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
229

Description

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Corporate Governance

Krystal Biotech, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Krystal Biotech, Inc. Earnings Call

Related Tickers

MRUS Merus N.V.
39.81
-1.63%
 
BPMC Blueprint Medicines Corporation
86.85
-2.31%
 
CRNX Crinetics Pharmaceuticals, Inc.
42.97
-0.09%
 
IDYA IDEAYA Biosciences, Inc.
37.13
-1.30%
 
ARGX argenx SE
360.23
+0.51%
 
ARVN Arvinas, Inc.
34.72
+1.25%
 
CYTK Cytokinetics, Incorporated
67.55
+0.82%
 
ACLX Arcellx, Inc.
51.65
-5.23%
 
PCVX Vaxcyte, Inc.
60.83
+0.35%
 
ANAB AnaptysBio, Inc.
19.87
+0.20%